CONNECT WITH US
Gaming

Gaming

Control Resonant sells 1 million copies in 3 weeks to become Remedy's fastest-selling game ever

PC Gamer logo

Published on

Add as a preferred source on Google
Control Resonant sells 1 million copies in 3 weeks to become Remedy's fastest-selling game ever

Remedy announced today that Control Resonant has surpassed one million copies sold, moving past Alan Wake 2 to become "the fastest-selling game in Remedy Entertainment's 31-year history."

Thank you for the support ❤️ For playing, sharing, and being a part of the community.#CONTROLResonant

Three weeks to a million copies isn't exactly a blistering pace by conventional videogame standards: The Blood of Dawnwalker hit the mark in three days, Wardogs did it in one, and Subnautica 2 put out twice that number in just 12 hours.

But despite producing a string of unique, memorable, and critically acclaimed games, Remedy has never really smashed a massive home run in the sales department. Even Alan Wake 2, which won numerous awards for narrative and art direction in 2023 (and would have claimed so many more if not for the Baldur's Gate 3 behemoth) took two months to sell a million copies, significantly outpacing the original Control and making it the studio's fastest-selling game at that time.

Remedy's more pressing problem, though, is profit: It took more than a year, and two million copies sold, before Alan Wake 2 actually started making money for Remedy. Addressing that shortcoming was the top priority for Jean-Charles Gaudechon, who took over as the company's new CEO in February: Remedy chairman Henri Österlund said at the time that Gaudechon's appointment was intended "to lead Remedy into a phase of profitable growth."

So far, Gaudechon seems to like what he sees from Control Resonant, calling the million-sold mark "a very strong start."


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.